Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
Condition(s):Acute Heart FailureLast Updated:February 16, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Acute Heart FailureLast Updated:February 16, 2024Recruiting
Condition(s):Diabetes Mellitus, Type 2Last Updated:April 4, 2016Completed
Condition(s):Hematocrit Change; Cardiovascular Prevention; Empagliflozin; SGLT2-Inhibitors; Tissue OxygenationLast Updated:February 29, 2024Recruiting
Condition(s):Heart Failure; Diabetes MellitusLast Updated:September 18, 2020Completed
Condition(s):Chronic Kidney Disease stage3Last Updated:July 14, 2021Unknown status
Condition(s):Gestational DiabetesLast Updated:January 23, 2023Recruiting
Condition(s):Acute Heart FailureLast Updated:March 7, 2024Recruiting
Condition(s):Adult Congenital Heart Disease; Heart FailureLast Updated:February 15, 2024Not yet recruiting
Condition(s):Myocardial InfarctionLast Updated:August 31, 2021Not yet recruiting
Condition(s):Heart Failure With Reduced Ejection FractionLast Updated:February 5, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.